Table 1.
Clinical characteristics of the included patients. N/A, not available; TKI, tyrosine kinase inhibitor.
| N = 1960 | |
|---|---|
| Age, years (range) | 63.0 (55.0–71.0) |
| Gender, n (%) | |
| Male | 1176 (60.0%) |
| Female | 784 (40.0%) |
| Smoking, n (%) | |
| No | 955 (48.7%) |
| Yes | 847 (43.2%) |
| N/A | 158 (8.1%) |
| Stage, n (%) | |
| I | 165 (8.4%) |
| II | 85 (4.3%) |
| III | 349 (17.8%) |
| IV | 1361 (69.4%) |
| Histology, n (%) | |
| Squamous cell carcinoma | 245 (12.5%) |
| Adenocarcinoma | 1423 (72.6%) |
| Small cell carcinoma | 133 (6.8%) |
| Others | 159 (8.1%) |
| First-line treatment, n (%) | |
| Chemotherapy | 1284 (65.5%) |
| Tyrosine kinase inhibitor (TKI) EGFR-TKI Gefitinib Erlotinib Afatinib Osimertinib ALK-inhibitor Crizotinib Ceritinib Alectinib Brigatinib |
658 (33.6%) 630 (32.1%) 182 (9.3%) 269 (13.7%) 145 (7.4%) 34 (1.7%) 28 (1.4%) 14 (0.7%) 3 (0.1%) 8 (0.4%) 3 (0.1%) |
| Immune checkpoint inhibitor | 18 (1.0%) |
| HBV serology, n (%) | |
| Positive HBsAg | 366 (18.7%) |
| Negative HBsAg and negative anti-HBs | 314 (16.0%) |
| Negative HBsAg and positive anti-HBs | 1280 (65.3%) |